Bioyond Robotics, a Shanghai-based intelligent automation company, has reportedly raised around RMB 200 million (USD 29 million) through Series A and A+ financing rounds. The Series A+ funding was co-led by BioTrack Capital and Lilly Asia Fund (LAV), with CICC Qide Fund, a subsidiary of CICC Capital, joining the round. This was complemented by continued follow-on investment from previous shareholders Qiming Venture Capital, Sequoia China Seed Fund, and Zhangke Harun Fund.
Company Background and Financing History
Founded in 2021, Bioyond has successfully closed four financing rounds, totaling RMB 300 million (USD 43.63 million). The funds from the latest round will be allocated towards product research and development, platform construction, market expansion, and further growth initiatives.
Core Technology Platforms and System Capabilities
Bioyond prides itself on its three core technology platforms: robotics, automation, data, and cloud. These platforms enable the flexible combination and rapid deployment of an automation system based on a full stack of self-developed high-performance flexible robots, a rich array of instrument modules, and user-friendly intelligent software. Equipped with an advanced artificial intelligence and computing engine, the system can process massive amounts of data, providing R&D and production personnel with reliable scientific analysis and a solid decision-making foundation.-Fineline Info & Tech
